Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Hemoglobinopathies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Market Overview:

The global hemoglobinopathies market reached a value of US$ 8.36 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 14.8 Billion by 2027 exhibiting a CAGR of 9.50% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Hemoglobinopathies is genetic blood disorder that causes structural and production abnormalities in hemoglobin molecules. Sickle cell, thalassemia, hemoglobin C, and beta-thalassemia are some of the common types of hemoglobinopathies. Hemoglobinopathies are detected by genetic testing, hemoglobin by high-performance liquid chromatography, routine red blood cell (RBC) count, hemoglobin isoelectric focusing (Hb IEF), and hemoglobin electrophoresis (Hb ELP) test. Pale skin, shortness of breath, cold hands or feet, tiredness, pain, and swelling in the hands and feet are a few of the most common symptoms hemoglobinopathies. Some of the widely used hemoglobinopathies treatment solutions include antibiotics, ACE inhibitors, stem-cell transplantation, blood transfusions, hydroxyurea, and analgesic.

 

 
 

www.imarcgroup.com

Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

Hemoglobinopathies Market Trends:

The increasing prevalence of various medical conditions, such as sickle cell disease (SCD) and thalassemia, is one of the key factors driving the growth of the market. Hemoglobinopathies are caused by abnormal hemoglobin that deforms and damages red blood cells and makes them hard and sticky. In line with this, the rising prevalence of anemia, especially among the geriatric population, which is also susceptible to various other chronic ailments, is favoring the market growth. Various technological advancements, such as the development of CRISPR-Cas9 technology to cure hemoglobinopathies by editing, removing, adding, or altering genes and modifying the DNA, are providing an impetus to the market growth. In line with this, the widespread adoption of gene therapy for the treatment of hemoglobinopathy is favoring market growth. Other factors, such as the significant expansion in the healthcare industry, along with the implementation of various government initiatives to promote research and development (R&D) activities to introduce novel therapies for treating hemoglobinopathies at affordable costs is anticipated to provide a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hemoglobinopathies market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, treatment, test type and end user.

Breakup by Type:

  • Thalassemia
    • Alpha Thalassemia
    • Beta Thalassemia
  • Sickle Cell Disease
  • Others
     

Breakup by Treatment:

 

 
 

www.imarcgroup.com

Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.

To get more information about this market, Request Sample

  • Blood Transfusion
  • Stem-cell Transplantation
  • Analgesics
  • Antibiotics
  • ACE Inhibitors
  • Hydroxyurea
  • Others
     

Breakup by Test Type:

  • Red Blood Cell (RBC) Count
  • Genetic Testing
  • High Performance Liquid Chromatography (HPLC)
  • Hemoglobin Isoelectric Focusing (Hb IEF)
  • Hemoglobin Electrophoresis (Hb ELP)
  • Hemoglobin Solubility Test
     

Breakup by End User:

  • Hospitals and Clinics
  • Diagnostics Laboratories
  • Others
     

Breakup by Region:

 

 
 

www.imarcgroup.com

To get more information on the regional analysis of this market, Request Sample

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Bio-Rad Laboratories Inc., bluebird bio Inc., Bristol-Myers Squibb Company, Danaher Corporation, Emmaus Life Sciences Inc., Gamida-Cell Ltd., Global Blood Therapeutics Inc., Novartis AG, PerkinElmer Inc., Pfizer Inc., Prolong Pharmaceuticals LLC, Sangamo Therapeutics Inc. and Sysmex Corporation.

Report Coverage:

Report Features Details
Base Year of the Analysis 2021
    Historical Period 2016-2021
Forecast Period 2022-2027
Units US$ Billion
Segment Coverage Type, Treatment, Test Type, End User, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Bio-Rad Laboratories Inc., bluebird bio Inc., Bristol-Myers Squibb Company, Danaher Corporation, Emmaus Life Sciences Inc., Gamida-Cell Ltd., Global Blood Therapeutics Inc., Novartis AG, PerkinElmer Inc., Pfizer Inc., Prolong Pharmaceuticals LLC, Sangamo Therapeutics Inc. and Sysmex Corporation.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

1    Preface
2    Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

    4.1    Overview
    4.2    Key Industry Trends
5    Global Hemoglobinopathies Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6    Market Breakup by Type
    6.1    Thalassemia
        6.1.1 Market Trends
        6.1.2 Key Segments
           6.1.2.1 Alpha Thalassemia
           6.1.2.2 Beta Thalassemia
        6.1.3 Market Forecast
    6.2    Sickle Cell Disease
        6.2.1 Market Trends
        6.2.2 Market Forecast
    6.3    Others
        6.3.1 Market Trends
        6.3.2 Market Forecast
7    Market Breakup by Treatment
    7.1    Blood Transfusion
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Stem-cell Transplantation
        7.2.1 Market Trends
        7.2.2 Market Forecast
    7.3    Analgesics
        7.3.1 Market Trends
        7.3.2 Market Forecast
    7.4    Antibiotics
        7.4.1 Market Trends
        7.4.2 Market Forecast
    7.5    ACE Inhibitors
        7.5.1 Market Trends
        7.5.2 Market Forecast
    7.6    Hydroxyurea
        7.6.1 Market Trends
        7.6.2 Market Forecast
    7.7    Others
        7.7.1 Market Trends
        7.7.2 Market Forecast
8    Market Breakup by Test Type
    8.1    Red Blood Cell (RBC) Count
        8.1.1 Market Trends
        8.1.2 Market Forecast
    8.2    Genetic Testing
        8.2.1 Market Trends
        8.2.2 Market Forecast
    8.3    High Performance Liquid Chromatography (HPLC)
        8.3.1 Market Trends
        8.3.2 Market Forecast
    8.4    Hemoglobin Isoelectric Focusing (Hb IEF)
        8.4.1 Market Trends
        8.4.2 Market Forecast
    8.5    Hemoglobin Electrophoresis (Hb ELP)
        8.5.1 Market Trends
        8.5.2 Market Forecast
    8.6    Hemoglobin Solubility Test
        8.6.1 Market Trends
        8.6.2 Market Forecast
9    Market Breakup by End User
    9.1    Hospitals and Clinics
        9.1.1 Market Trends
        9.1.2 Market Forecast
    9.2    Diagnostics Laboratories
        9.2.1 Market Trends
        9.2.2 Market Forecast
    9.3    Others
        9.3.1 Market Trends
        9.3.2 Market Forecast
10    Market Breakup by Region
    10.1    North America
        10.1.1 United States
           10.1.1.1 Market Trends
           10.1.1.2 Market Forecast
        10.1.2 Canada
           10.1.2.1 Market Trends
           10.1.2.2 Market Forecast
    10.2    Asia-Pacific
        10.2.1 China
           10.2.1.1 Market Trends
           10.2.1.2 Market Forecast
        10.2.2 Japan
           10.2.2.1 Market Trends
           10.2.2.2 Market Forecast
        10.2.3 India
           10.2.3.1 Market Trends
           10.2.3.2 Market Forecast
        10.2.4 South Korea
           10.2.4.1 Market Trends
           10.2.4.2 Market Forecast
        10.2.5 Australia
           10.2.5.1 Market Trends
           10.2.5.2 Market Forecast
        10.2.6 Indonesia
           10.2.6.1 Market Trends
           10.2.6.2 Market Forecast
        10.2.7 Others
           10.2.7.1 Market Trends
           10.2.7.2 Market Forecast
    10.3    Europe
        10.3.1 Germany
           10.3.1.1 Market Trends
           10.3.1.2 Market Forecast
        10.3.2 France
           10.3.2.1 Market Trends
           10.3.2.2 Market Forecast
        10.3.3 United Kingdom
           10.3.3.1 Market Trends
           10.3.3.2 Market Forecast
        10.3.4 Italy
           10.3.4.1 Market Trends
           10.3.4.2 Market Forecast
        10.3.5 Spain
           10.3.5.1 Market Trends
           10.3.5.2 Market Forecast
        10.3.6 Russia
           10.3.6.1 Market Trends
           10.3.6.2 Market Forecast
        10.3.7 Others
           10.3.7.1 Market Trends
           10.3.7.2 Market Forecast
    10.4    Latin America
        10.4.1 Brazil
           10.4.1.1 Market Trends
           10.4.1.2 Market Forecast
        10.4.2 Mexico
           10.4.2.1 Market Trends
           10.4.2.2 Market Forecast
        10.4.3 Others
           10.4.3.1 Market Trends
           10.4.3.2 Market Forecast
    10.5    Middle East and Africa
        10.5.1 Market Trends
        10.5.2 Market Breakup by Country
        10.5.3 Market Forecast
11    SWOT Analysis
    11.1    Overview
    11.2    Strengths
    11.3    Weaknesses
    11.4    Opportunities
    11.5    Threats
12    Value Chain Analysis
13    Porters Five Forces Analysis

    13.1    Overview
    13.2    Bargaining Power of Buyers
    13.3    Bargaining Power of Suppliers
    13.4    Degree of Competition
    13.5    Threat of New Entrants
    13.6    Threat of Substitutes
14    Price Analysis
15    Competitive Landscape

    15.1    Market Structure
    15.2    Key Players
    15.3    Profiles of Key Players
        15.3.1    Bio-Rad Laboratories Inc.
           15.3.1.1 Company Overview
           15.3.1.2 Product Portfolio
           15.3.1.3 Financials
           15.3.1.4 SWOT Analysis
        15.3.2    bluebird bio Inc.
           15.3.2.1 Company Overview
           15.3.2.2 Product Portfolio
           15.3.2.3 Financials
           15.3.2.4 SWOT Analysis
        15.3.3    Bristol-Myers Squibb Company
           15.3.3.1 Company Overview
           15.3.3.2 Product Portfolio
           15.3.3.3 Financials
           15.3.3.4 SWOT Analysis
        15.3.4    Danaher Corporation
           15.3.4.1 Company Overview
           15.3.4.2 Product Portfolio
           15.3.4.3 Financials
           15.3.4.4 SWOT Analysis
        15.3.5    Emmaus Life Sciences Inc.
           15.3.5.1 Company Overview
           15.3.5.2 Product Portfolio
           15.3.5.3 Financials
        15.3.6    Gamida-Cell Ltd.
           15.3.6.1 Company Overview
           15.3.6.2 Product Portfolio
           15.3.6.3 Financials
        15.3.7    Global Blood Therapeutics Inc.
           15.3.7.1 Company Overview
           15.3.7.2 Product Portfolio
           15.3.7.3 Financials
        15.3.8    Novartis AG
           15.3.8.1 Company Overview
           15.3.8.2 Product Portfolio
           15.3.8.3 Financials
           15.3.8.4 SWOT Analysis
        15.3.9    PerkinElmer Inc.
           15.3.9.1 Company Overview
           15.3.9.2 Product Portfolio
           15.3.9.3 Financials
           15.3.9.4 SWOT Analysis
        15.3.10    Pfizer Inc.
           15.3.10.1 Company Overview
           15.3.10.2 Product Portfolio
           15.3.10.3 Financials
           15.3.10.4 SWOT Analysis
        15.3.11    Prolong Pharmaceuticals LLC
           15.3.11.1 Company Overview
           15.3.11.2 Product Portfolio
        15.3.12    Sangamo Therapeutics Inc.
           15.3.12.1 Company Overview
           15.3.12.2 Product Portfolio
           15.3.12.3 Financials
           15.3.12.4 SWOT Analysis
        15.3.13    Sysmex Corporation
           15.3.13.1 Company Overview
           15.3.13.2 Product Portfolio
           15.3.13.3 Financials
           15.3.13.4 SWOT Analysis

List of Figures

Figure 1: Global: Hemoglobinopathies Market: Major Drivers and Challenges
Figure 2: Global: Hemoglobinopathies Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Hemoglobinopathies Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Hemoglobinopathies Market: Breakup by Type (in %), 2021
Figure 5: Global: Hemoglobinopathies Market: Breakup by Treatment (in %), 2021
Figure 6: Global: Hemoglobinopathies Market: Breakup by Test Type (in %), 2021
Figure 7: Global: Hemoglobinopathies Market: Breakup by End User (in %), 2021
Figure 8: Global: Hemoglobinopathies Market: Breakup by Region (in %), 2021
Figure 9: Global: Hemoglobinopathies (Thalassemia) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: Global: Hemoglobinopathies (Thalassemia) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: Global: Hemoglobinopathies (Sickle Cell Disease) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: Global: Hemoglobinopathies (Sickle Cell Disease) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: Global: Hemoglobinopathies (Other Types) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: Global: Hemoglobinopathies (Other Types) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: Global: Hemoglobinopathies (Blood Transfusion) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: Global: Hemoglobinopathies (Blood Transfusion) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: Global: Hemoglobinopathies (Stem-cell Transplantation) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: Global: Hemoglobinopathies (Stem-cell Transplantation) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Global: Hemoglobinopathies (Analgesics) Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Global: Hemoglobinopathies (Analgesics) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: Global: Hemoglobinopathies (Antibiotics) Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: Global: Hemoglobinopathies (Antibiotics) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: Global: Hemoglobinopathies (ACE Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: Global: Hemoglobinopathies (ACE Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: Global: Hemoglobinopathies (Hydroxyurea) Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: Global: Hemoglobinopathies (Hydroxyurea) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: Global: Hemoglobinopathies (Other Treatments) Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: Global: Hemoglobinopathies (Other Treatments) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 29: Global: Hemoglobinopathies (Red Blood Cell (RBC) Count) Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: Global: Hemoglobinopathies (Red Blood Cell (RBC) Count) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: Global: Hemoglobinopathies (Genetic Testing) Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: Global: Hemoglobinopathies (Genetic Testing) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: Global: Hemoglobinopathies (High Performance Liquid Chromatography-HPLC) Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: Global: Hemoglobinopathies (High Performance Liquid Chromatography-HPLC) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: Global: Hemoglobinopathies (Hemoglobin Isoelectric Focusing-Hb IEF) Market: Sales Value (in Million US$), 2016 & 2021
Figure 36: Global: Hemoglobinopathies (Hemoglobin Isoelectric Focusing-Hb IEF) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 37: Global: Hemoglobinopathies (Hemoglobin Electrophoresis-Hb ELP) Market: Sales Value (in Million US$), 2016 & 2021
Figure 38: Global: Hemoglobinopathies (Hemoglobin Electrophoresis-Hb ELP) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 39: Global: Hemoglobinopathies (Hemoglobin Solubility Test) Market: Sales Value (in Million US$), 2016 & 2021
Figure 40: Global: Hemoglobinopathies (Hemoglobin Solubility Test) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 41: Global: Hemoglobinopathies (Hospitals and Clinics) Market: Sales Value (in Million US$), 2016 & 2021
Figure 42: Global: Hemoglobinopathies (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 43: Global: Hemoglobinopathies (Diagnostics Laboratories) Market: Sales Value (in Million US$), 2016 & 2021
Figure 44: Global: Hemoglobinopathies (Diagnostics Laboratories) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 45: Global: Hemoglobinopathies (Other End Users) Market: Sales Value (in Million US$), 2016 & 2021
Figure 46: Global: Hemoglobinopathies (Other End Users) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 47: North America: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 48: North America: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 49: United States: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 50: United States: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 51: Canada: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 52: Canada: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 53: Asia-Pacific: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 54: Asia-Pacific: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 55: China: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 56: China: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 57: Japan: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 58: Japan: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 59: India: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 60: India: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 61: South Korea: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 62: South Korea: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 63: Australia: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 64: Australia: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 65: Indonesia: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 66: Indonesia: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 67: Others: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 68: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 69: Europe: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 70: Europe: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 71: Germany: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 72: Germany: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 73: France: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 74: France: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 75: United Kingdom: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 76: United Kingdom: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 77: Italy: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 78: Italy: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 79: Spain: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 80: Spain: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 81: Russia: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 82: Russia: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 83: Others: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 84: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 85: Latin America: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 86: Latin America: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 87: Brazil: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 88: Brazil: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 89: Mexico: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 90: Mexico: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 91: Others: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 92: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 93: Middle East and Africa: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
Figure 94: Middle East and Africa: Hemoglobinopathies Market: Breakup by Country (in %), 2021
Figure 95: Middle East and Africa: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 96: Global: Hemoglobinopathies Industry: SWOT Analysis
Figure 97: Global: Hemoglobinopathies Industry: Value Chain Analysis
Figure 98: Global: Hemoglobinopathies Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Hemoglobinopathies Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Hemoglobinopathies Market Forecast: Breakup by Type (in Million US$), 2022-2027
Table 3: Global: Hemoglobinopathies Market Forecast: Breakup by Treatment (in Million US$), 2022-2027
Table 4: Global: Hemoglobinopathies Market Forecast: Breakup by Test Type (in Million US$), 2022-2027
Table 5: Global: Hemoglobinopathies Market Forecast: Breakup by End User (in Million US$), 2022-2027
Table 6: Global: Hemoglobinopathies Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 7: Global: Hemoglobinopathies Market: Competitive Structure
Table 8: Global: Hemoglobinopathies Market: Key Players


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Key Questions Answered in This Report

The global hemoglobinopathies market was valued at US$ 8.36 Billion in 2021.

We expect the global hemoglobinopathies market to exhibit a CAGR of 9.50% during 2022-2027.

The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective hemoglobinopathies treatment through blood transfusion procedure to mitigate the risk of coronavirus infection upon hospital visits.

The high prevalence of chronic blood-related medical conditions, such as Sickle Cell Disease (SCD) and thalassemia, along with the rising awareness towards wide presence of hemoglobinopathies treatment solutions, is primarily driving the global hemoglobinopathies market.

Based on the type, the global hemoglobinopathies market has been segregated into thalassemia, sickle cell disease, and others. Currently, sickle cell disease holds the largest market share.

Based on the treatment, the global hemoglobinopathies market can be bifurcated into blood transfusion, stem-cell transplantation, analgesics, antibiotics, ACE inhibitors, hydroxyurea, and others. Among these, blood transfusion treatment currently represents the majority of the total market share.

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Some of the major players in the global hemoglobinopathies market include Bio-Rad Laboratories Inc., bluebird bio Inc., Bristol-Myers Squibb Company, Danaher Corporation, Emmaus Life Sciences Inc., Gamida-Cell Ltd., Global Blood Therapeutics Inc., Novartis AG, PerkinElmer Inc., Pfizer Inc., Prolong Pharmaceuticals LLC, Sangamo Therapeutics Inc., and Sysmex Corporation.

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 2499

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links

4